Cumberland Pharmaceuticals' Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

For most adults, a resting heart rate range of 60 to 100 beats per minute (bpm) is typical: However, a number of factors—including physical activity levels, stress and medication—can impact ...

19, 2025 — People with pockets of fat hidden inside their muscles are at a higher risk of dying or being hospitalized from a heart attack or heart failure ... oxygen treatment as a potential ...

A newborn was sent to NICU after a Visalia OB-GYN failed to check their fetal heart and inaccurately recommended a C-section ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Restriction of sodium intake - < 3 g/day or < 7 g/sodium chloride (table salt) - is one of the non-pharmacological measures recommended by the Brazilian Guidelines on Heart Failure 1 and by the ...

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti ...

Novo Nordisk NVO is scheduled to report fourth-quarter 2024 results on Feb. 5, 2025, before the opening bell. The Zacks ...

SARS-CoV-2 infection was associated with more rapid coronary plaque progression and significantly increased risk for adverse ...

Background Primary prevention strategies for cardiovascular disease (CVD) conventionally rely on 10-year risk estimates of ...

Transparency Notifications from Shareholders Ghent, Belgium - 3 February 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of ...

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, announced today that it will ...